Emerging treatment options for myelofibrosis: Focus on pacritinib

Vivian Chow, Ashley Weissman, Casey Lee O’Connell, Azim Mehrvar, Mojtaba Akhtari

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Myelofibrosis (MF) is a myeloid malignancy associated with a heavy symptomatic burden that decreases quality of life and presents a risk for leukemic transformation. While there are limited curative treatments, the recent discovery of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway dysregulation has led to many clinical investigations for new treatment approaches. This review provides practical knowledge on the disease state, an overview of treatment options, and specifically focuses on the efficacy and safety of pacritinib in the management of MF. Pacritinib is a novel selective inhibitor of JAK2 and FMS-related tyrosine kinase 3 (FLT3) currently in Phase III trials for the treatment of MF. Thus far, studies have demonstrated clinical efficacy in reducing splenomegaly and constitutional symptoms. Common adverse events were gastrointestinal in nature, while hematologic toxicity was limited. However, it was announced that all ongoing clinical trials on pacritinib have been placed on hold by the US Food and Drug Administration in February 2016, due to concerns for increased intracranial hemorrhage and cardiac events. With comprehensive risk-benefit analysis of clinical trial data, the utility of pacritinib in the management of MF may be more clearly defined.

Original languageEnglish (US)
Pages (from-to)2655-2665
Number of pages11
JournalOncoTargets and Therapy
Volume9
DOIs
StatePublished - May 4 2016

Keywords

  • FLT3
  • JAK2
  • Myeloproliferative neoplasms
  • SB1518

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Emerging treatment options for myelofibrosis: Focus on pacritinib'. Together they form a unique fingerprint.

Cite this